---
title: "BGMSP.US (BGMSP.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/BGMSP.US/news.md"
symbol: "BGMSP.US"
name: "BGMSP.US"
parent: "https://longbridge.com/zh-HK/quote/BGMSP.US.md"
datetime: "2026-03-16T14:28:26.479Z"
locales:
  - [en](https://longbridge.com/en/quote/BGMSP.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BGMSP.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BGMSP.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/BGMSP.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/BGMSP.US/news.md)


# BGMSP.US (BGMSP.US) — 相關新聞

### [BioNxt Solutions sichert exklusive Rechte an innovativer Chaperon-Technologie für orale Thin-Film-Drug-Delivery](https://longbridge.com/zh-HK/news/274936105.md)
*2026-02-05T08:05:20.000Z*
### [Reeflex Solutions Delays Annual Financial Filings Amid Audit Complications](https://longbridge.com/zh-HK/news/274049697.md)
*2026-01-28T22:00:18.000Z*
### [BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion | BNXTF Stock News](https://longbridge.com/zh-HK/news/273669321.md)
*2026-01-26T00:05:00.000Z*
> BioNxt Solutions Inc. has made significant progress in its cladribine oral thin film (ODF) program for Multiple Sclerosi

### [BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS) | BNXTF Stock News](https://longbridge.com/zh-HK/news/273194604.md)
*2026-01-21T00:05:00.000Z*
> BioNxt Solutions Inc. has reported final preclinical results from a pig study showing that its sublingual oral dissolvab

### [BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 10-Q: FY2025 Q3 Revenue: USD 81 K](https://longbridge.com/zh-HK/news/265800433.md)
*2025-11-13T22:20:58.000Z*
### [BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 8-K: FY2025 Q3 Revenue: USD 81 K](https://longbridge.com/zh-HK/news/265799291.md)
*2025-11-13T22:13:48.000Z*
### [CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 10-Q: FY2025 Q2 Revenue: USD 0](https://longbridge.com/zh-HK/news/253011792.md)
*2025-08-14T10:09:33.000Z*
### [CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 8-K: FY2025 Q2 Revenue: USD 0](https://longbridge.com/zh-HK/news/252922713.md)
*2025-08-13T21:28:48.000Z*